Drug Trial Radar · NCT03619213
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,263
Actual
Start
Aug 27, 2018
Primary completion
Mar 27, 2022
Study completion Mar 27, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
DapagliflozinDrug
10 mg tablets given once daily, per oral use.
PlaceboDrug
Placebo matching dapagliflozin 10 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.Time frame: Up to 42.1 months
- Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% SubpopulationTime frame: Up to 42.1 months
Locations
348 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Fairhope, Alabama
Research Site
Mobile, Alabama
Research Site
Sheffield, Alabama
Research Site
Tucson, Arizona
Research Site
Little Rock, Arkansas
Research Site
Beverly Hills, California
Research Site
Loma Linda, California
Research Site
Los Angeles, California
Research Site
Stamford, Connecticut
Research Site
Clearwater, Florida
Research Site
Miami, Florida
Research Site
Naples, Florida
Research Site
Ocala, Florida
Research Site
Ormond Beach, Florida
Research Site
Port Charlotte, Florida
Research Site
Saint Augustine, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Chicago, Illinois
Research Site
Gurnee, Illinois
Research Site
Anderson, Indiana
Research Site
Munster, Indiana
Research Site
Louisville, Kentucky
Research Site
Hammond, Louisiana
Research Site
Houma, Louisiana
Research Site
Monroe, Louisiana
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Bay City, Michigan
Research Site
Flint, Michigan
Research Site
Flint, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Rochester, Minnesota
Research Site
Saint Paul, Minnesota
Research Site
Kansas City, Missouri
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
Great Falls, Montana
Research Site
Las Vegas, Nevada
Research Site
Lebanon, New Hampshire
Showing 40 of 348 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.